#Fl2000 download plus

Inclusion and exclusion criteria, study design and follow-up assessment have been previously described 9 and high tumor burden definition is available in the Online Supplementary Appendix. Patients aged 18вЂ“75 years with grade 1, 2 or 3a FL were eligible for this open-label randomized trial. The Follicular Lymphoma International Prognostic Index score was strongly associated with outcome for both event-free and overall survival in univariate analysis and its prognostic value remained highly significant after adjusting for other significant covariates in multivariate models ( P 8 years) of R-chemotherapy in patients with de novo FL enrolled in a randomized trial. With a median follow up of 8.3 years, addition of rituximab remained significantly associated with prolonged event-free survival (primary end point) ( P=0.0004) with a trend towards a benefit for overall survival ( P=0.076).

#Fl2000 download plus

Between May 2000 and May 2002, 358 newly diagnosed patients with high tumor burden follicular lymphoma were randomized to receive cyclophosphamide, adriamycin, etoposide and prednisolone plus interferon-О±2a or a similar chemotherapy-based regimen plus rituximab, and outcome was up-dated. > 5 years) of these trials is yet available. Four randomized trials demonstrated a clinical benefit for patients treated with rituximab. Anti-CD20-containing chemotherapy regimens have become the standard of care for patients with follicular lymphoma needing cytotoxic therapy.